Long-term persistence of immunity after hepatitis B vaccination: Is this substantiated by the literature?

Lao, Terence T.

doi:10.1080/21645515.2016.1267084

Cited by 9 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They do not provide any information about long-term protection received by complete primary immunisation and booster doses. Thus, even fully vaccinated people may not have any detectable titre at the moment of investigation (92,93). Moreover, in some publications the de nition of complete or incomplete vaccination status was not reported (and not all differentiated between incomplete and complete vaccination), which may have resulted in an overestimation of VC and must be considered when interpreting the results.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B Vaccination Coverage in Germany: Systematic Review

Steffen

Sperle

Harder

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Despite being considered as a low prevalence country for hepatitis B (HBV), some populations in Germany are at higher risk of infection. In the context of the World Health Organization’s (WHO) viral hepatitis elimination goals a valid epidemiological data base is needed to plan and monitor the national response. Prevention strategies include general and targeted HBV vaccination programmes. Objective: The aim of this work was to estimate the HBV vaccination coverage (VC) in the general population (GP) and different population groups in Germany from available evidence and to identify current evidence gaps for future research.Methods: We conducted a systematic review on HBV VC in the general population and populations at high risk of HBV exposure or severe infection in Germany. We included eligible publications (01/01/2017 to 06/06/2020) from databases Embase, Pubmed and Livivo, from a previous scoping review (including data published 01/01/2005-17/03/2017), from the national surveillance system and screened the reference lists of all publications at full text level. Risk of bias was assessed using the Hoy et al tool. Results: We included 68 publications of 67 studies and assigned them to the respective population groups. Twenty-one studies contained data among children/adolescents and three among adults from the GP (VC 65.8% - 90.5% and 22.9% - 52.1%, respectively), one among travellers to HBV endemic countries (VC 89%), 13 among immunocompromised populations (VC 11.5% - 89%), 16 among populations with occupational risk and 16 with non-occupational risk of HBV exposure (VC 63.6% - 96.5% and 4.4% - 52%, respectively). Conclusion: Comprehensive evidence at low risk of bias was identified for children/adolescents. owever, 25 years after including HBV in the national immunisation schedule, VC in Germany is still below the 95%-goal defined by WHO. For people at occupational risk of HBV exposure, VC was mostly reported to be over the WHO goal of 80%, but quality of evidence was heterogenous and should be improved. For people at non-occupational risk of HBV exposure, evidence was sparse and of low quality. The low VC highlights the need for future research to plan vaccination programmes targeting these populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B Vaccination Coverage in Germany: Systematic Review

Steffen

Sperle

Harder

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…They do not provide any information about long-term protection received by complete primary immunisation and booster doses. Thus, even fully vaccinated people may not have any detectable titre at the moment of investigation [ 90 , 91 ]. Moreover, in some publications the definition of complete or incomplete vaccination status was not reported (and not all differentiated between incomplete and complete vaccination), which may have resulted in an overestimation of VC and must be considered when interpreting the results.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B vaccination coverage in Germany: systematic review

et al. 2021

View full text Add to dashboard Cite

Background Despite being considered as a low prevalence country for hepatitis B (HBV), some populations in Germany are at higher risk of infection. In the context of the World Health Organization’s (WHO) viral hepatitis elimination goals, a valid epidemiological data base is needed to plan and monitor the national response. Prevention strategies include general and targeted HBV vaccination programmes. Objective The aim of this work was to estimate the HBV vaccination coverage (VC) in the general population (GP) and different population groups in Germany from available evidence and to identify current evidence gaps for future research. Methods We conducted a systematic review on HBV VC in the general population and populations at high risk of HBV exposure or severe infection in Germany. We included eligible publications (01/01/2017 to 06/06/2020) from databases Embase, Pubmed and Livivo, from a previous scoping review (including data published 01/01/2005–17/03/2017), from the national surveillance system and screened the reference lists of all publications at full text level. Risk of bias was assessed using the Hoy et al. tool. Results We included 68 publications of 67 studies and assigned them to one or more suitable population groups. Twenty-one studies contained data among children/adolescents and three among adults from the GP (VC 65.8–90.5% and 22.9–52.1%, respectively), one among travelers (VC 89.0%), 13 among immunocompromised populations (VC 7.8–89.0%), 16 among populations with occupational risk and 16 with non-occupational risk of HBV exposure (VC 63.6–96.5% and 4.4–84.5%, respectively). Conclusion Comprehensive evidence at low risk of bias was identified for children/adolescents. However, 25 years after including HBV in the national immunisation schedule, VC in Germany is still below the 95%-goal defined by WHO. For people at occupational risk of HBV exposure, VC was mostly reported to be over the WHO goal of 80%, but quality of evidence was heterogenous and should be improved. For people at non-occupational risk of HBV exposure, evidence was sparse and of low quality. The low VC highlights the need for future research to plan vaccination programmes targeting these populations.

show abstract

“…However, the duration of the immunity protection of the vaccine was unknown, as well as the necessity for a booster vaccination. [15][16][17][18][19] Theoretically, anti-HBs level below 10 mIU/mL is considered as threshold for the effective protection against HBV infection. However, the individual with anti-HBs < 10 mIU/mL is not under the threat from HBV infection because of immune memory related to HBsAg.…”

Section: Discussionmentioning

confidence: 99%

Long-term protection at 20–31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community

Zhou

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: To assess the long-term protection conferred by plasma-derived hepatitis B vaccine at 20-31y after primary immunization during infancy in Chinese rural community. Method: Participants born between 1986 and 1996, who received a full course of primary vaccination with plasma-derived hepatitis B vaccine and had no experience with booster vaccination were enrolled. An epidemiological investigation was performed, and blood samples were collected to detect hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc). The positive rate of HBsAg, anti-HBs, and anti-HBc were calculated to evaluate the long-term protection of the plasma-derived hepatitis B vaccine. Results: A total of 949 participants were enrolled in the final analysis. Six subjects were detected to be HBsAg-positive, resulting in a HBsAg carrier rate of 0.63% (6/949). A total of 468 (52.41%) participants maintained a level of anti-HBs antibody ≥10 mIU/mL, with a GMC of 112.20 mIU/mL (95%CI: 97.721 28.82 mIU/mL). A significant downtrend was observed in the anti-HBs positive rate (P < .001). The average anti-HBc positive rate was 5.90% (56/949), increased with prolongation of immunization (P < .001). Conclusions: The plasma-derived hepatitis B vaccine maintained satisfactory protection at 20-31 y after primary immunization. These results indicate that a booster dose is not necessary. Further studies on the immune memory induced by the plasma-derived hepatitis B vaccine are needed.

show abstract

Long-term persistence of immunity after hepatitis B vaccination: Is this substantiated by the literature?

Cited by 9 publications

References 20 publications

Hepatitis B Vaccination Coverage in Germany: Systematic Review

Hepatitis B Vaccination Coverage in Germany: Systematic Review

Hepatitis B vaccination coverage in Germany: systematic review

Long-term protection at 20–31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community

Contact Info

Product

Resources

About